Quick Answer
MIRA PHARMACEUTICALS, INC. reported Net Income of -$10.44 million for fiscal year 2025.
MIRA PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$10.44M -33.0% |
-$7.85M +34.5% |
-$11.98M -69.8% |
-$7.06M | — |
| Diluted EPS | -$1.35 -164.7% |
-$0.51 +40.0% |
-$0.85 -112.5% |
-$0.40 | — |
| Total Assets | $11.09M +279.5% |
$2.92M -40.7% |
$4.93M +474.8% |
$858.1K | — |
| Cash and Equivalents | $6.35M +124.0% |
$2.83M | — | — | — |
| Stockholders Equity | $10.39M +372.4% |
$2.20M -49.7% |
$4.37M +833.7% |
-$596.2K -126.4% |
$2.26M |
| R&D Expense | $1.72M -48.0% |
$3.31M +110.1% |
$1.57M -33.1% |
$2.35M | — |
| Shares Outstanding | 41.94M +153.2% |
16.56M +12.0% |
14.78M +11.0% |
13.31M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.14M | +44.3% | +26.0% |
| Diluted EPS | September 30, 2025 | -$1.18 | -742.9% | -1211.1% |
| Total Assets | September 30, 2025 | $7.63M | +78.9% | +779.1% |
| Cash and Equivalents | September 30, 2025 | $2.64M | — | +261.6% |
| Stockholders Equity | September 30, 2025 | $7.55M | +111.2% | +1224.8% |
| R&D Expense | September 30, 2025 | $412.6K | -61.3% | -16.8% |
| Shares Outstanding | September 30, 2025 | 39.51M | +142.9% | +127.3% |
- MIRA PHARMACEUTICALS, INC. reported Net Income of -$10.44 million for fiscal year 2025.
- MIRA PHARMACEUTICALS, INC. showed a decrease of -33.0% in Net Income compared to the prior fiscal year.
- MIRA PHARMACEUTICALS, INC. reported Diluted EPS of $1.35 per share (loss) for fiscal year 2025.
- MIRA PHARMACEUTICALS, INC. showed a decrease of -164.7% in Diluted EPS compared to the prior fiscal year.
- MIRA PHARMACEUTICALS, INC. reported Total Assets of $11.09 million for fiscal year 2025.
- MIRA PHARMACEUTICALS, INC. showed an increase of +279.5% in Total Assets compared to the prior fiscal year.
- MIRA PHARMACEUTICALS, INC. reported Cash and Equivalents of $6.35 million for fiscal year 2025.
- MIRA PHARMACEUTICALS, INC. showed an increase of +124.0% in Cash and Equivalents compared to the prior fiscal year.
- MIRA PHARMACEUTICALS, INC. reported Stockholders Equity of $10.39 million for fiscal year 2025.
- MIRA PHARMACEUTICALS, INC. showed an increase of +372.4% in Stockholders Equity compared to the prior fiscal year.
- MIRA PHARMACEUTICALS, INC. reported R&D Expense of $1.72 million for fiscal year 2025.
- MIRA PHARMACEUTICALS, INC. showed a decrease of -48.0% in R&D Expense compared to the prior fiscal year.
- MIRA PHARMACEUTICALS, INC. reported Shares Outstanding of 41.94 million shares for fiscal year 2025.
- MIRA PHARMACEUTICALS, INC. showed an increase of +153.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: